As of today (2026-06-25), the Forward Annual Dividend Yield of argenx SE is 0.00%.
As of today (2026-06-25), the Trailing Annual Dividend Yield of argenx SE is 0.00%.
MEX:ARGXN's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.495 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
argenx SE (MEX:ARGXN) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
MEX:ARGXN vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, argenx SE's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where argenx SE's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
argenx SE (MEX:ARGXN) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #999999 out of 146 companies in the Biotechnology industry.
Is argenx SE's Forward Dividend Yield % too high?
argenx SE's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, argenx SE ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, argenx SE has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #999999 out of 146 companies for Forward Dividend Yield %. This places argenx SE in the lower half of its industry. The industry median Forward Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.50, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
argenx SE (MEX:ARGXN) has a current Forward Dividend Yield % of 0.00%. The stock's GF Value™ is MXN20,951.12, compared to a current price of MXN13,000.67 — trading 37.9% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. argenx SE's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For argenx SE (MEX:ARGXN), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (MEX:ARGXN) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of MXN13,000.67 is trading 37.9% below its estimated GF Value™ of MXN20,951.12.
Key valuation signals for MEX:ARGXN:
Forward Dividend Yield %: 0.00%
GF Value™: MXN20,951.12 vs. price of MXN13,000.67 (37.9% below fair value)
No single metric tells the full story. See the MEX:ARGXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
63GF Score
Get the complete analysis for MEX:ARGXN
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ARGXN has been successfully added to your 